The HER2 paradox: HER2-positive branch cells found in HER2-negative breast cancer


Dec. 14, 2012 ? A multicenter investigate led by researchers during UC Davis describes new, enigmatic characteristics of a many common form of breast cancer. The commentary strew light on how a illness can hedge diagnosis and could urge diagnosis and diagnosis of breast cancer.

The research, led by Jian Jian Li, executive of translational investigate in a UC Davis Department of Radiation Oncology, examined breast tumors formerly suspicion to miss a HER2 protein, which, when over-expressed, is compared with illness recurrence. Instead, researchers found in a tumors tiny groups of aggressive, treatment-resistant HER2-positive breast cancer branch cells (BCSCs). The commentary will be published Dec. 15 in Clinical Cancer Research.

“These BSCSs are really resistant to normal treatments, that can lead patients to relapse,” pronounced Li, a investigate lead author. “Despite chemotherapy, radiotherapy or even surgery, a cancer is still recurrent. These commentary change a judgment of breast cancer since now we know HER2-negative breast cancers can be treated effectively with anti-HER2 treatments.”

In a past decade scientists and clinicians have grown a improved bargain of how breast cancers differ on a mobile level. Whether a growth contains HER2, an estrogen receptor protein, a progesterone receptor protein or all 3 or nothing can have an huge impact on a tumor’s aggressiveness, a patient’s altogether augury and diagnosis choices.

HER2-positive breast cancers are customarily treated with drugs that aim a HER2 protein, such as Herceptin or Tykerb, with good results. However, until recently, there has been small reason to discharge these targeted treatments to patients with HER2-negative cancer.

The team, that enclosed researchers from a University of Michigan Comprehensive Cancer Center, a Holden Comprehensive Cancer Center during a University of Iowa, Emory University School of Medicine and MD Anderson Cancer Center, removed a HER2-positive BCSCs from irradiated, HER2-negative breast tumors. They also analyzed a branch cells for CD44 and CD24, dungeon aspect proteins that prove cancer aggressiveness and act as BCSC markers.

The organisation found that a HER2-positive, CD44 positive, CD24 negative/low BCSCs were some-more assertive and rarely resistant to radiotherapy. These characteristics were significantly reduced by Herceptin or brief interfering RNA. HER2 and CD44 certain BCSCs were found in 57.1 percent of primary tumors and 84.6 percent of memorable tumors.

In serve to identifying this formerly dark organisation of HER2-positive branch cells, serve hearing supposing new insights into how these BCSCs say their insurgency to treatment. A formidable network of proteins, including HER2 and STAT3, allay metastasis, automatic dungeon genocide and other functions. As a result, these cells tarry a progression of normal anti-cancer therapies.

“We feel this investigate will have a vital scientific, as good as clinical, impact,” says Li. “We now have a improved bargain of how BCSCs conflict deviation and other treatments.”

While new investigate has shown that patients with HER2-negative breast cancer can indeed advantage from HER2 treatments, before to this work no one accepted a mechanisms. This investigate provides minute acknowledgment that HER2 diagnosis can potentially urge outcomes in HER2-negative breast cancers.

In serve to opening adult new diagnosis options for HER2-negative patients, a investigate also provides a evidence pathway. Markers, such as CD44, could assistance clinicians brand aggressive, HER2-positive BCSCs in cancers that are evidently HER2-negative, individualizing diagnosis to compare any patient’s needs. These commentary might also allege diagnosis for other cancers.

“This might open a probability of treating HER2-positive branch cells in bone, lung or mind cancers, that are all formidable to yield in a after stages,” says Li.

Other authors were Nadire Duru, Ming Fan, Demet Candas, Cheikh Menaa, Hsin-Chen Liu, Danupon Nantajit, Kai Xiao, Angela Eldridge and Kit S. Lam, during UC Davis, Yunfei Wen during MD Anderson, Brett A. Chromy during UC Davis and Lawrence Livermore, Shiyong Li during Emory University, Douglas R. Spitz, Holden Comprehensive Cancer Center and Max S. Wicha during a University of Michigan Comprehensive Cancer Center.

This investigate was upheld by a National Institutes of Health Grant CA133402, CA152313, and by a U.S. Department of Energy Office of Science Grant DE-SC0001271.

Other amicable bookmarking and pity tools:


Story Source:

The above story is reprinted from materials supposing by University of California – Davis Health System.

Note: Materials might be edited for calm and length. For serve information, greatfully hit a source cited above.


Note: If no author is given, a source is cited instead.

Disclaimer: This essay is not dictated to yield medical advice, diagnosis or treatment. Views voiced here do not indispensably simulate those of ScienceDaily or the staff.

Source: Health Medicine Network